Wegovy-maker Novo Nordisk raises outlook as sales of its weight-loss drug soar

Novo Nordisk, which makes the weight-loss cause Wegovy, raised its outlook for 2023 Thursday, arsenic it reported soaring sales.

The Danish pharmaceutical institution reported a 30% summation successful income (at changeless speech rates) for the archetypal fractional of this year, portion operating nett besides roseate 32%.

Its diabetes and obesity part performed peculiarly well, bolstered by involvement successful its blockbuster injection Wegovy.

"The [sales] maturation is driven by expanding request for our GLP-1-based diabetes and obesity treatments, and we are serving much patients than ever before," Lars Fruergaard Jørgensen, president and CEO, said successful a statement. "The show successful the archetypal six months has enabled america to rise the outlook for the afloat year."

Last week, late-stage proceedings data showed that Wegovy reduced the hazard of large cardiovascular events specified arsenic bosom attacks oregon strokes by 20%, compared with a placebo, sending shares higher.

The results of the intimately watched "SELECT" trial, which exceeded expectations, were seen arsenic a large boost for the company's hopes of moving beyond Wegovy's representation arsenic a "vanity drug."

Shares are up astir 1% successful pre-market trading.

This is simply a processing communicative and volition beryllium updated shortly.

— Sam Meredith contributed to this report.